Related Experiment Video

Updated: Aug 8, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Troglitazone: a possible modulator of ovarian steroidogenesis

Mohamed F M Mitwally1, Selma F Witchel, Robert F Casper

  • 1Reproductive Sciences Division, Department of Obstetrics and Gynecology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.

Journal of the Society for Gynecologic Investigation
|May 16, 2002
PubMed
Abstract

Insights

Troglitazone directly impacts ovarian steroidogenesis by reducing androgen and progesterone production in cultured cells. This suggests its benefits in polycystic ovary syndrome (PCOS) may involve more than just improving insulin sensitivity.

Area of Science:

  • Endocrinology
  • Reproductive Biology
  • Pharmacology

Background:

  • Troglitazone enhances insulin sensitivity and improves metabolic disturbances in polycystic ovary syndrome (PCOS).
  • The precise mechanisms underlying troglitazone's effects in PCOS, specifically regarding direct impacts on ovarian steroidogenesis, remain unclear.
  • Investigating direct effects on ovarian cells is crucial to understanding troglitazone's therapeutic potential in PCOS.

Purpose of the Study:

  • To determine if troglitazone directly affects ovarian steroidogenesis.
  • To investigate troglitazone's impact on androgen production in rat theca interstitial cells (rTICs).
  • To assess troglitazone's effect on progesterone production in human granulosa lutein cells (hGLCs).

Main Methods:

  • Primary cultures of rat theca interstitial cells (rTICs) and human granulosa lutein cells (hGLCs) were established.
  • Cells were treated with troglitazone, insulin, luteinizing hormone (LH), and human chorionic gonadotropin (hCG), individually and in combination.
  • Androsterone and progesterone levels in culture media were quantified.

Main Results:

  • Troglitazone significantly decreased basal and stimulated androsterone production by rTICs in a dose-dependent manner.
  • Troglitazone also reduced basal and stimulated progesterone production by hGLCs in a dose-dependent manner.
  • These effects were observed independently of insulin, LH, or hCG stimulation.

Conclusions:

  • Troglitazone exerts a direct inhibitory effect on ovarian androgen and progesterone production.
  • These findings indicate that troglitazone's therapeutic benefits in PCOS may stem from both improved peripheral insulin sensitivity and direct modulation of ovarian steroidogenesis.
  • Further research is warranted to elucidate the clinical implications of troglitazone's direct actions on ovarian function.

More Related Videos

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...